Publication date: 24 November 2026 Source: Blood Advances, Volume 10, Issue 22 Author(s): Charles J. Milrod, Anna Chorzalska, Dennis Bonal, John Morgan, Makayla Pardo, Thomas A. Ollila, Ari Pelcovits, Christina Raker, Diana O. Treaba, Jessica McMahon, Stephen Donnelly, Caylee Carmody, Jeannine Margolis, Matthew Matasar, Scott Huntington, Patrycja M. Dubielecka, Adam J. Olszewski
Peripheral CD8+ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma. // Blood Advances. – URL: https://www.sciencedirect.com/science/article/pii/S2473952926006440?dgcid=rss_sd_all
Peripheral CD8+ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma. Blood Advances. https://www.sciencedirect.com/science/article/pii/S2473952926006440?dgcid=rss_sd_all
“Peripheral CD8+ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma.” Blood Advances.
@article{article38196,
title = {Peripheral CD8+ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma},
journal = {Blood Advances},
url = {https://www.sciencedirect.com/science/article/pii/S2473952926006440?dgcid=rss_sd_all}
}